|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weintraub MD, Li QQ and Agarwal PK:
Advances in intravesical therapy for the treatment of non-muscle
invasive bladder cancer (Review). Mol Clin Oncol. 2:656–660. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Booth CM, Siemens DR, Li G, Peng Y,
Tannock IF, Kong W, Berman DM and Mackillop WJ: Perioperative
chemotherapy for muscle-invasive bladder cancer: A population-based
outcomes study. Cancer. 120:1630–1638. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sfakianos JP, Kim PH, Hakimi AA and Herr
HW: The effect of restaging transurethral resection on recurrence
and progression rates in patients with nonmuscle invasive bladder
cancer treated with intravesical bacillus Calmette-Guérin. J Urol.
191:341–345. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Even-Ram S and Yamada KM: Cell migration
in 3D matrix. Curr Opin Cell Biol. 17:524–532. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Way JC and Chalfie M: mec-3, a
homeobox-containing gene that specifies differentiation of the
touch receptor neurons in C. Elegans. Cell. 54:5–16. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Karlsson S and Ahrén B: Insulin and
glucagon secretion in swimming mice: Effects of autonomic receptor
antagonism. Metabolism. 39:724–732. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chew CS, Parente JA Jr, Zhou C, Baranco E
and Chen X: Lasp-1 is a regulated phosphoprotein within the cAMP
signaling pathway in the gastric parietal cell. Am J Physiol.
275:C56–C67. 1998.PubMed/NCBI
|
|
9
|
Grunewald TG and Butt E: The LIM and SH3
domain protein family: Structural proteins or signal transducers or
both? Mol Cancer. 7:312008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Grunewald TG, Kammerer U, Schulze E,
Schindler D, Honig A, Zimmer M and Butt E: Silencing of LASP-1
influences zyxin localization, inhibits proliferation and reduces
migration in breast cancer cells. Exp Cell Res. 312:974–982. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Grunewald TG, Kammerer U, Winkler C,
Schindler D, Sickmann A, Honig A and Butt E: Overexpression of
LASP-1 mediates migration and proliferation of human ovarian cancer
cells and influences zyxin localisation. Br J Cancer. 96:296–305.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Traenka C, Remke M, Korshunov A, Bender S,
Hielscher T, Northcott PA, Witt H, Ryzhova M, Felsberg J, Benner A,
et al: Role of LIM and SH3 protein 1 (LASP1) in the metastatic
dissemination of medulloblastoma. Cancer Res. 70:8003–8014. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ardelt P, Grunemay N, Strehl A, Jilg C,
Miernik A, Kneitz B and Butt E: LASP-1, a novel urinary marker for
detection of bladder cancer. Urol Oncol. 31:1591–1598. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Payton S: Bladder cancer: LASP-1-a
promising urine marker for detection of bladder cancer. Nat Rev
Urol. 9:2402012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Z, Chen Y, Wang X, Zhang H, Zhang Y,
Gao Y, Weng M, Wang L, Liang H, Li M, et al: LASP-1 induces
proliferation, metastasis and cell cycle arrest at the G2/M phase
in gallbladder cancer by down-regulating S100P via the PI3K/AKT
pathway. Cancer Lett. 372:239–250. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kubota Y, Nakada T, Yanai H, Kakizaki H,
Sasagawa I and Watanabe M: Electropermeabilization in bladder
cancer chemotherapy. Cancer Chemother Pharmacol. 39:67–70. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hisazumi H, Uchibayashi T, Katoh M,
Kobayashi T, Nakajima K, Naitoh K, Misaki T and Kuroda K:
Anticancer drug sensitivity in vitro in the bladder cancer cell
line, KK-47 and prophylactic use of carbazilquinone and urokinase
in bladder cancer. Urol Res. 9:231–235. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tsuboi S, Sutoh M, Hatakeyama S, Hiraoka
N, Habuchi T, Horikawa Y, Hashimoto Y, Yoneyama T, Mori K, Koie T,
et al: A novel strategy for evasion of NK cell immunity by tumours
expressing core2 O-glycans. EMBO J. 30:3173–3185. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stölting M, Wiesner C, van Vliet V, Butt
E, Pavenstädt H, Linder S and Kremerskothen J: Lasp-1 regulates
podosome function. PLoS One. 7:e353402012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sutoh M, Hashimoto Y, Yoneyama T, Yamamoto
H, Hatakeyama S, Koie T, Okamoto A, Yamaya K, Saitoh H, Funyu T, et
al: Invadopodia formation by bladder tumor cells. Oncol Res.
19:85–92. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamamoto H, Sutoh M, Hatakeyama S,
Hashimoto Y, Yoneyama T, Koie T, Saitoh H, Yamaya K, Funyu T,
Nakamura T, et al: Requirement for FBP17 in invadopodia formation
by invasive bladder tumor cells. J Urol. 185:1930–1938. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoneyama Sutoh M, Hatakeyama S, Habuchi T,
Inoue T, Nakamura T, Funyu T, Wiche G, Ohyama C and Tsuboi S:
Vimentin intermediate filament and plectin provide a scaffold for
invadopodia, facilitating cancer cell invasion and extravasation
for metastasis. Eur J Cell Biol. 93:157–169. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tomasetto C, Moog-Lutz C, Regnier CH,
Schreiber V, Basset P and Rio MC: Lasp-1 (MLN 50) defines a new LIM
protein subfamily characterized by the association of LIM and SH3
domains. FEBS Lett. 373:245–249. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shimizu F, Shiiba M, Ogawara K, Kimura R,
Minakawa Y, Baba T, Yokota S, Nakashima D, Higo M, Kasamatsu A, et
al: Overexpression of LIM and SH3 Protein 1 leading to accelerated
G2/M phase transition contributes to enhanced tumourigenesis in
oral cancer. PLoS One. 8:e831872013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Caldieri G, Ayala I, Attanasio F and
Buccione R: Cell and molecular biology of invadopodia. Int Rev Cell
Mol Biol. 275:1–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Linder S, Wiesner C and Himmel M:
Degrading devices: Invadosomes in proteolytic cell invasion. Annu
Rev Cell Dev Biol. 27:185–211. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Murphy DA and Courtneidge SA: The ‘ins’
and ‘outs’ of podosomes and invadopodia: Characteristics, formation
and function. Nat Rev Mol Cell Biol. 12:413–426. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Imanishi K, Yoneyama MS, Hatakeyama S,
Yamamoto H, Koie T, Saitoh H, Yamaya K, Funyu T, Nakamura T, Ohyama
C and Tsuboi S: Invadopodia are essential in transurothelial
invasion during the muscle invasion of bladder cancer cells. Mol
Med Rep. 9:2159–2165. 2014.PubMed/NCBI
|
